Gastroskopische Befunde und Blutungshäufigkeit unter der Therapie mit herkömmlichen nichtsteroidalen Antirheumatika, selektiven COX-2 Inhibitoren und low dose AcetylsalicylsäureFrau Diplom Mediziner Regina Neitzel1.1.1.121.2.31.3.4562.673.3.1.7891011621#6393.2.12133.3.144.4.1.1415621#60916653#4404.2.17641#440184.2.1.19621#5034.3.4.3.1.587#4764.3.2.201001#5514.3.3.21621#6454.3.4.1013#4964.3.5.221007#4884.3.6.234.3.7.613#38124624#431254.3.8.621#3632627624#4574.4.4.4.1.28583#3874.4.2.295.29303132333435363738396.39404142434445AbkürzungslisteLiteraturverzeichnisEidesstattliche ErklärungDanksagungdeInhaltsverzeichnisHilfe Literaturverzeichnis 1. Ballinger A, Smith G. COX-2 inhibitors vs. NSAIDs in gastrointestinal damage and prevention. Expert Opin Pharmacother 2001;2 :31-40 2. Barkun AN, Cockeram AW, Plourde V, Fedorak RN. Acid suppression in non- variceal acute upper gastrointestinal bleeding. Aliment Pharmacol Ther 1999;13:1565-1584 3. Bensen WG, Fiechtner JJ, McMillen JI, Zhao WW, Yu SS, Woods EM, et al. Treatment of osteoarthritis with celecoxib, a cyclooxygenase-2 inhibitor: A randomized controlled trial. Mayo Clin Proc 1999;74 :1095-1105 4. Bianchi Porro G, Parente F, Imbevi V, Montrone F, Caruso J . Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazol dual therapy. Gut 1996;39 :22-26 5. Bolten WW. Meine Meinung zum Thema: „ NSAR- induzierte Ulcera: Therapie und Prävention“. Z Rheumatol 1995;54 :9-11 6. Bolten WW, Lang B, Wagner AV, Krobot KJ. Konsequenzen und Kosten der NSAR- Gastropathie in Deutschland. Akt Rheumatologie 24; 1999 :127-134 7. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000;343 :1520-1528 8. Bombardier C. An evidence- based evaluation of gastrointestinal safety of coxibs. Am J Cardiol 2002;89 :3-9 9. Brune K, Kalden J, Zacher J, Zeilhofer HU. Selektive Inhibitoren der Zyclooxygenase- 2. Dt Ärztebl 2000; 97 : A-1815-1817 10. Catella-Lawson F, Reilly MP, Kapoor SC, Cucchiara AJ, DeMarco S, Tournier B, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345 :1809-1817 11. Chan FK, Sung JY, Chung SC, To KF, Yung MY, Leung VK, et al. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti- inflammatory drug therapy to prevent peptic ulcers. Lancet 1997;350 :975-979 12. Chan FKL, Sung JJY, Suen R, Lee YT, WU CY, Leung WK, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti- inflammmatory drug associated bleeding peptic ulcers? A prospective randomizised study. Aliment Pharmacol Ther 1998;12 :1201-1205 13. Chan FK, Chung SC, Suen BY, Lee JT, Leung WK, Leung VK, et al . Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low dose aspirin or naproxen. N Engl J Med 2001;344 :967-973 14. Chan FK, Hung LC, Suen BY, Lee KC, Wu JC, Leung VK, et al . Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in Patients with arthritis. N Engl Med 2002;347 :2104-2110 15. Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs 2000;59 :957-980 16. Crofford LJ. COX- 1 and COX- 2 Tissue Expression: Implications and Predictions. J Rheumatology 1997;24 ;(Suppl 49):15-19 17. Dannhardt G, Hahn L. COX- 2- Inhibitoren: Aktueller Stand und Ausblick. Pharm Unserer Zeit 2000;29 :100-106 18. Deeks JJ, Smith LA, Bradlay MD. Efficacy, tolerability and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002;325 :607-608 19. Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta- analysis, BMJ 2000;321 :1183-1187 20. Emery P, Zeidler H, Kvien TK, Guslandi M, Naudin R, Stead H, et al. Celecoxib versus diclofenac in long- term management of rheumatoid arthritis: randomised double- blind comparison; Lancet 1999;354 :2106-2111 21. Fendrick AM. Developing an economic rationale for the use of selective COX- 2 inhibitors for patients at risk for NSAID gastropathy. Cleve Clin J Med 2002;69 ;(Suppl 1):I59-64 22. Fiegel G. Unterschiede in der Verträglichkeit und Interaktion von klassischen Antirheumatika und COX- 2- Hemmern. Der Kassenarzt 2000;45 :37-38 23. Fisch UW, Brauer H-G, Mahr G, Vergin H. Cyclooxygenase- 2- spezifische Inhibitoren: Grundlegende Aspekte des Wirkmechanismus. Akt Rheumatologie 1999;24 :63-68 24. Fries JF, Miller SR, Spitz PW, Williams CA, Hubert HB, Bloch DA. Toward an epidemiology of gastropathy associated with nonsteroidal antiinflammatory drug use. Gastroenterology 1989;96 :647-655 25. Fries JF. NSAID Gastropathy: The second most deadly rheumatic disease? Epidemiology and risk appraisal. J Rheumatol 1991;18 ;(Suppl 28):6-10 26. Fux R, Mörike K, Gleiter C. Celecoxib- Gegenwärtiger Stellenwert in der Arzneimitteltherapie; Arzneimitteltherapie 2001;19 :307-317 27. Graham DY, Al-Assi MT, Genta RM, Karttunen TJ. Ulcer site and complications: relation to Helicobacter pylori infection and NSAID use. Endoskopy 1996;28 :229-233 28. Gross WL . Neue Formen der Rheumatherapie. Dt Ärztebl 2000;97 :A-1818-1825 29. Hawkey CJ, Tulassay Z, Szczepanski L, van Rensburg CJ, Filipowicz-Sosnowska A, Lanas A, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non- steroidal anti- inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998;352 :1016-1021 30. Hawkey CJ, Karrasch JA, Szczepanski l, Walker DG, Barkun A, Swannell AJ, et al. Omeprazole compared with misoprostol for ulcers associated with non- steroidal anti- inflammatory drugs. Omeprazole versus Misoprostol for NSAID- induced Ulcer Management (Omnium) Study Group. N Engl J Med 1998;338 :727-734 31. Hawkey CJ . COX-2 Inhibitors. Lancet 1999;353 :307-314 32. Hawkey CJ. What consideration should be given to Helicobacter pylori in treating nonsteroidal anti- inflammatory drug ulcers? Eur J Gastroenterol Hepatol 2000;12 ;(Suppl 1):17-20 33. Hawkey CJ. NSAIDs and COX-2 Inhibitors: what can we learn from large outcomes trials? The gastroenterologist’s perspective. Clin Exp Rheumatol 2001;19 ;(Suppl 25):23-30 34. Hinz B, Brune K . COX- 1 und COX- 2: Funktionen und pharmakologische Beeinflussung. Pharm Unserer Zeit 1999;28 :21-29 35. Klebl FH, Schölmerich J, Lock G. Prophylaxe und Therapie NSAR- induzierter gastroduodenaler Schleimhautschäden. Internistische Praxis 2001;41 :137-140 36. Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, et al. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001;104 :2280-2288 37. Laheij RJ, Jansen JB, Verbeek AL, Verheugt FW. Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease. Aliment Pharmacol Ther 2001;15 :1055-1059 38. Lai KC, Lam SK, Chu KM, Hui WM, Wong BC, Hu WH, et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002;346 :2033-2038 39. Lai KC, Lau Cs, Ip WY, Hui WM, Wong CY, Hu W, et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003;17 :799-805 40. Laine L, Harper S, Simon T, Bath R, Johanson J, Schwartz H, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis. Rofecoxib Osteoarthritis Endoskopy Study Group. Gastroenterology 1999;117 :776-783 41. Lanas A, Bajador E, Serrano P, Fuentes J, Carreno S, Guardia J, et al. Nitrovasodilators, low- dose aspirin, other non- steroidal anti- inflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000;343 :834-839 42. Lanza FL, Royer GL, Nelson RS, Chen TT, Seckmann CE, Rack MF. A comperative endoscopic evaluation of the damaging effects of nonsteroidal antiinflammatory agents on the gastric and duodenal mucosa. Am J Gastroenterol 1981;75 :17-21 43. Layton D, Rilay J, Wilton LV, Shakir SA. Safety profile of rofecoxib as used in general practice in England: results of a prescription- event monitoring study. Br J Clin Pharmacol 2003;55 :166-174 44. Lipsky PE. Defining COX-2 inhibitors. J Rheumatol 2000;27 ;(Suppl. 60):13-16 45. Mamdani M, Rochon PA, Juurlink DN, Kopp A, Andreson GM, Nagalie G, et al. A. Observational study of upper gastrointestinal haemorrage in elderly patients given selective cyclo-oxygenase- 2 inhibitors or conventional non- steroidal anti- inflammatory drugs. BMJ 2002;325 :624-630 46. McCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAID. Best Pract Res Clin Gastroenterol 2001;15 :755-773 47. McMurray RW, Hardy KJ. COX- 2 inhibitors: today and tomorrow. Am J Med Sci 2002;323 :181-189 48. Miehle W. Nichtsteroidale Antiphlogistika und Cyclooxygenase- 2- spezifische Hemmsubstanzen. Dtsch Med Wochenschr 1999;149 :541-545 49. Neeck G. Neue Strategien in der medikamentösen Behandlung der rheumatoiden Arthritis. Med Welt 2000;51 :237-241 50. Ng TM, Fock KM, Khor JL, Teo EK, Sim CS, Tan AL, et al. Non- steroidal anti- inflammatory drugs, Helicobacter pylori and bleeding gastric ulcer. Aliment Pharmacol Ther 2000;14 :203-209 51. Nielsen GL, Sorensen HAT, Mellemkjoer L, Blot WJ, McLaughin JK, Tage-Jensen U, et al. Risk of hospitalization resulting from upper gastrointestinal bleeding amaong patients taking corticosteroids: a register-based cohort study. Am J Med 2001;111 :541-545 52. Peterson KU, Bolten WW, Darius H, Forst R, Hollenz M, Ihme N, et al . Spectrum NSAR. Arzneimitteltherapie heute, Aesopus-Verlag

Stuttgart

, 1998 53. Rösch W. NSAR- induzierte Ulcera- Therapie und Prävention. Z Rheumatol 1995;54 :2-9 54. Sachs L. Angewandte Statistik. 7. Auflage, Springer-Verlag

Berlin Heidelberg New-York

, 1992 55. Scheiman JM. Outcomes studies of the gastrointestinal safety of cyclooxygenase- 2 inhibitors. Cleve Clin J Med 2002;69 ;(Suppl 1):140-146 56. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib versus non- steroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS- study: A randomized controlled trial. Celecoxib longterm arthritis safety study, JAMA 2000;284 :1247-1255 57. Simon LS, Weaver AL, Graham DY, Kivitz AJ, Lipsky PE, Hubbard RC, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized, controlled trial, JAMA 1999,282 :1921-1928 58. Stichtenoth DO, Frölich JC. Antiphlogistische Pharmakotherapie. Klinikarzt 2000;29 :219-223 59. Stichtenoth DO, Frölich JC. Therapie mit präferentiellen und spezifischen COX- 2- Inhibitoren. Internist 2001;42 :421-426 60. Vane JR . Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat New Biol 1971;231 :232-235 61. Yeomans ND, Tulassay Z, Juhasz L, Racz I, Howard JM, Van Rensburg CJ, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial. Ranitidin versus omeprazole for NSAID- associated ulcer treatment (Astronaut) Study Group. N Engl J Med 1998;338 :719-726